NFL Biosciences SA (ALNFL.PA)
EUR 1.88
(-2.59%)
EUR 1.88
(-2.59%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -4.04 Million EUR | -53.63% |
| 2022 | -2.8 Million EUR | -231.93% |
| 2021 | -1.07 Million EUR | -210.73% |
| 2020 | -271.09 Thousand EUR | 9.07% |
| 2019 | -303.6 Thousand EUR | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | -827.23 Thousand EUR | 53.19% |
| 2023 FY | - EUR | -53.63% |
| 2023 Q4 | -1.92 Million EUR | 21.34% |
| 2023 Q2 | -2.44 Million EUR | -42.98% |
| 2022 Q4 | -1.71 Million EUR | -37.14% |
| 2022 FY | - EUR | -231.93% |
| 2022 Q2 | -1.24 Million EUR | 0.0% |
| 2021 FY | - EUR | -210.73% |
| 2021 Q2 | -200.46 Thousand EUR | 0.0% |
| 2020 FY | - EUR | 9.07% |
| 2019 FY | - EUR | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| ABIONYX Pharma SA | -3.29 Million EUR | -23.079% |
| ABIVAX Société Anonyme | -133.2 Million EUR | 96.96% |
| Adocia SA | -22.73 Million EUR | 82.187% |
| Aelis Farma SA | -6.34 Million EUR | 36.201% |
| Biophytis S.A. | -13.8 Million EUR | 70.666% |
| Advicenne S.A. | -6.24 Million EUR | 35.149% |
| genOway Société anonyme | 6.35 Million EUR | 163.761% |
| IntegraGen SA | -52.5 Thousand EUR | -7612.515% |
| Medesis Pharma S.A. | -3.84 Million EUR | -5.317% |
| Neovacs S.A. | -8.44 Million EUR | 52.077% |
| Plant Advanced Technologies SA | 72.53 Thousand EUR | 5682.934% |
| Quantum Genomics Société Anonyme | -2.87 Million EUR | -40.92% |
| Sensorion SA | -22.31 Million EUR | 81.853% |
| Theranexus Société Anonyme | -7.38 Million EUR | 45.185% |
| TME Pharma N.V. | -5.07 Million EUR | 20.164% |
| Valbiotis SA | -6.95 Million EUR | 41.779% |
| TheraVet SA | -517.33 Thousand EUR | -682.722% |
| Valerio Therapeutics Société anonyme | -18.91 Million EUR | 78.593% |
| argenx SE | -199.5 Million EUR | 97.97% |
| BioSenic S.A. | -6.79 Million EUR | 40.416% |
| Celyad Oncology SA | -7.76 Million EUR | 47.838% |
| DBV Technologies S.A. | -79.53 Million EUR | 94.909% |
| Galapagos NV | 51.03 Million EUR | 107.934% |
| Genfit S.A. | -28.05 Million EUR | 85.565% |
| GeNeuro SA | -14.31 Million EUR | 71.718% |
| Hyloris Pharmaceuticals SA | -14.98 Million EUR | 72.969% |
| Innate Pharma S.A. | -7.57 Million EUR | 46.565% |
| Inventiva S.A. | -101.84 Million EUR | 96.024% |
| MaaT Pharma SA | -19.74 Million EUR | 79.487% |
| MedinCell S.A. | -20.04 Million EUR | 79.8% |
| Nanobiotix S.A. | -34.01 Million EUR | 88.097% |
| Onward Medical N.V. | -35.23 Million EUR | 88.507% |
| Oryzon Genomics S.A. | -4.43 Million EUR | 8.663% |
| OSE Immunotherapeutics SA | -23.26 Million EUR | 82.596% |
| Oxurion NV | -16.72 Million EUR | 75.795% |
| Pharming Group N.V. | 4.98 Million EUR | 181.296% |
| Poxel S.A. | -12.17 Million EUR | 66.752% |
| GenSight Biologics S.A. | -21.73 Million EUR | 81.365% |
| Transgene SA | -27.02 Million EUR | 85.016% |
| Financière de Tubize SA | 184.57 Thousand EUR | 2293.899% |
| UCB SA | 1.26 Billion EUR | 100.319% |
| Valneva SE | -64.51 Million EUR | 93.724% |
| Vivoryon Therapeutics N.V. | -28.35 Million EUR | 85.718% |